BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12823855)

  • 1. Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1.
    D'Elia HF; Mattsson LA; Ohlsson C; Nordborg E; Carlsten H
    Arthritis Res Ther; 2003; 5(4):R202-9. PubMed ID: 12823855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines and bone loss in a 5-year longitudinal study--hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study.
    Abrahamsen B; Bonnevie-Nielsen V; Ebbesen EN; Gram J; Beck-Nielsen H
    J Bone Miner Res; 2000 Aug; 15(8):1545-54. PubMed ID: 10934653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis.
    D'Elia HF; Larsen A; Mattsson LA; Waltbrand E; Kvist G; Mellström D; Saxne T; Ohlsson C; Nordborg E; Carlsten H
    J Rheumatol; 2003 Jul; 30(7):1456-63. PubMed ID: 12858441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial.
    Pullerits R; d'Elia HF; Tarkowski A; Carlsten H
    Rheumatology (Oxford); 2009 Jul; 48(7):785-90. PubMed ID: 19416946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies.
    Usón J; Balsa A; Pascual-Salcedo D; Cabezas JA; Gonzalez-Tarrio JM; Martín-Mola E; Fontan G
    J Rheumatol; 1997 Nov; 24(11):2069-75. PubMed ID: 9375862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
    Kotake S; Sato K; Kim KJ; Takahashi N; Udagawa N; Nakamura I; Yamaguchi A; Kishimoto T; Suda T; Kashiwazaki S
    J Bone Miner Res; 1996 Jan; 11(1):88-95. PubMed ID: 8770701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456].
    Forsblad d'Elia H; Christgau S; Mattsson LA; Saxne T; Ohlsson C; Nordborg E; Carlsten H
    Arthritis Res Ther; 2004; 6(5):R457-68. PubMed ID: 15380045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6.
    Abrahamsen B; Stilgren LS; Rettmer E; Bonnevie-Nielsen V; Beck-Nielsen H
    Calcif Tissue Int; 2003 Jan; 72(1):18-23. PubMed ID: 12384814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis.
    Oelzner P; Franke S; Lehmann G; Eidner T; Hein G; Wolf G
    Rheumatol Int; 2012 Jan; 32(1):199-206. PubMed ID: 20821212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of bone mineral density and turnover in patients with cystic fibrosis: associations between the IGF system and inflammatory cytokines.
    Street ME; Spaggiari C; Ziveri MA; Volta C; Federico G; Baroncelli GI; Bernasconi S; Saggese G
    Horm Res; 2006; 66(4):162-8. PubMed ID: 16804317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of exercise training on bone remodeling, insulin-like growth factors, and bone mineral density in postmenopausal women with and without hormone replacement therapy.
    Milliken LA; Going SB; Houtkooper LB; Flint-Wagner HG; Figueroa A; Metcalfe LL; Blew RM; Sharp SC; Lohman TG
    Calcif Tissue Int; 2003 Apr; 72(4):478-84. PubMed ID: 12574871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
    Robak T; Gladalska A; Stepień H; Robak E
    Mediators Inflamm; 1998; 7(5):347-53. PubMed ID: 9883970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6, soluble interleukin-2-receptor and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: influences of disease activity and drug therapy.
    Franke S; Herrmann D; Hein G; Müller A; Stein G
    Eur J Med Res; 1997 Sep; 2(9):401-6. PubMed ID: 9300938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood.
    Rogers A; Eastell R
    J Bone Miner Res; 1998 Oct; 13(10):1577-86. PubMed ID: 9783546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis.
    Forsblad d'Elia H; Pullerits R; Carlsten H; Bokarewa M
    Rheumatology (Oxford); 2008 Jul; 47(7):1082-7. PubMed ID: 18511473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.